COSTS OF HEALTH SERVICES UTILIZATION OF PEOPLE WITH FETAL ALCOHOL SPECTRUM DISORDER BY SEX AND AGE GROUP IN ALBERTA, CANADA

Main Article Content

Nguyen Xuan Thanh
Egon Jonsson

Keywords

FASD, cost, health services utilization, Alberta, Canada

Abstract

Objectives


To estimate the annual health services utilization (HSU) cost per person with FASD by sex and age; the lifetime HSU cost per person with FASD by sex, and the annual HSU cost of FASD for Alberta by sex.


Methods


The HSU costs of FASD including physician, outpatient, and inpatient services were described by sex and age. The costs per person-year were estimated by multiplying the average number of hospitalizations, outpatient visits, and physician visits per person-year by the average cost of each service. The annual HSU cost of FASD for Alberta was estimated by multiplying the annual HSU cost per person with FASD by the number of people living with FASD in Alberta in 2012. The lifetime HSU cost per person with FASD was estimated by sex for several lifespans ranging from 10 to 70 years.


Results


The annual cost of HSU for people with FASD in Alberta was $25 9 million, of which FAS accounted for 26%. The annual HSU cost per person with FAS and FASD were $6, 2 00 and $5, 6 00, respectively. The incremental annual HSU cost per person with FAS is $ 4,100 and with FASD is $3, 4 00 as compared to the general population. The lifetime (70 years) HSU cost per person with FAS was $ 506, 000 and with FASD was $2 45, 000. Males had higher HSU costs than females. HSU costs of FAS and FASD varied greatly by age group.


Conclusion


The findings suggest that FASD is a public health issue in Alberta and can be used for economic evaluations of FASD intervention and/or prevention in the province.

Abstract 167 | PDF Downloads 54

References

1. Popova S, Lange S, Burd L, Chudley AE, Clarren SK, et al. (2013) Cost of Fetal Alcohol Spectrum Disorder Diagnosis in Canada. PLoS ONE 8(4): e60434. doi:10.1371/journal.pone.0060434
2. Popova S, Lange S, Burd L, Urbanoski K, Rehm J . Cost of specialized addiction treatment of clients with fetal alcohol spectrum disorder in Canada. BMC Public Health 2013; 13:570.
3. Stade B, Ungar WJ, Stevens B, Beyene J, Koren G. The burden of prenatal exposure to alcohol: measurement of cost. JFAS Int 2006 Feb; 4: e5 .
4. Bank of Canada. Inflation Calculator, available at : www.bankofcanada.ca/rates/related/inflation - calculator/?page_m oved=1 (accessed October 29, 2014) . Costs of health services utilization of people with fetal alcohol spectrum disorder by sex and age group in Alberta, Canada J Popul Ther Clin Pharmacol Vol 21(3): e42 1 - e4 30; November 1 7, 2014 © 2014 Canadian Society of Pharmacology and Therapeutics. All rights reserved. e 430
5. Stade B, Ali A, Bennett D, Campbell D, Johnston M, Lens C, Tran S, Koren G. The burden of prenatal exposure to alcohol: revised measurement of cost. Can J Clin Pharmacol 2009;16(1): e91 - e102 .
6. Fuchs D, Burnside L, De Rivi ere L, Brownell M, Marchenski S, Mudry A, and Dahl M. Economic impact of children in care with FASD and parental alcohol issues Phase 2: Costs and service utilization of health care, special education, and child care. Ottawa: Centre of Excellence for Child Welfare 2009.
7. Thanh NX, Jonsson E . Costs of fetal alcohol spectrum disorder in Alberta, Canada. Canadian Journal of Clinical Pharmacology 2009; 16: e80 - e90.
8. Thanh NX, Jonsson E, Dennett L, Jacobs P. Costs of FASD. In: Riley EP, Clarren S, Weinberg J, Jonsson E (Eds). Fetal alcohol spectrum disorder: Management and policy perspectives of FASD. Wiley Blackwell 2011.
9. Thanh NX, Jonsson E, Salmon A, Sebastianski M. Incidence and prevalence of Fetal Alcohol Spectrum Disorder by sex and age group in Alberta, Canada. J Popul Ther Clin Pharmacol Vol 21(3):e395 - e404; October 29, 2014.
10. Stratton KR, Howe CJ, Battaglia FC. Fetal alcohol syndrome diagnosis, epidemiology, prevention, and treatment. Washington DC: Institute of Medicine, National Academy Press, 1996.
11. Klug MG, Burd L. Fetal alcohol syndrome prevention: annual and cumulative cost savings. Neurotoxicology and Teratology 2003;25:763 - 765.